Why dosing starts low
The dose-escalation schedule (increasing every four weeks toward the maintenance dose) exists because GI tolerability is dose-dependent. Starting at the maintenance dose predictably maximizes nausea.
Approved dose ranges
Wegovy (weight management): maintenance doses up to 2.4 mg weekly. Ozempic (type 2 diabetes): up to 2.0 mg weekly. Rybelsus (oral): titrated to 14 mg daily. Different indications, different maxima — the label is the reference.
Why weekly timing matters
The ~1-week half-life supports weekly dosing; missed-dose rules in the label exist to avoid doubling up after long gaps. Consistency matters more than clockwork precision.
Why we stop here
Publications that go further — dose-finding for compounded product, self-titration schedules — describe a different product category (unregulated) and a different risk world. The evidence on this site describes approved medicine.
References
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med 2021. [source]
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-Like Peptide-1. Cell Metab 2018. [source]
- ClinicalTrials.gov — registered semaglutide studies. [source]
Evidence tier: Approved medicine · Last reviewed: 2026-09-05 · Sources cited below.